AR076020A1 - Anticuerpos contra la proteina tweak humana y usos de los mismos - Google Patents
Anticuerpos contra la proteina tweak humana y usos de los mismosInfo
- Publication number
- AR076020A1 AR076020A1 ARP100101066A ARP100101066A AR076020A1 AR 076020 A1 AR076020 A1 AR 076020A1 AR P100101066 A ARP100101066 A AR P100101066A AR P100101066 A ARP100101066 A AR P100101066A AR 076020 A1 AR076020 A1 AR 076020A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- tweak protein
- same
- antibodies against
- against human
- Prior art date
Links
- 101000830598 Homo sapiens Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 title 1
- 102000058177 human TNFSF12 Human genes 0.000 title 1
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 abstract 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un anticuerpo que se une a la proteína TWEAK, caracterizado por una union a la proteína TWEAK que se caracteriza porque comprende como dominio variable de cadena pesada una CDR3H seleccionada de entre el grupo que consiste en las secuencias SEC ID N° 8, 16 o 24. Composicion farmacéutica que comprende dicho anticuerpo, ácido nucleico que codifica el anticuerpo, vectores que comprenden los ácidos nucleicos, células huéspedes que incluyen vectores, y método para produccion de dicho anticuerpo son objetos proporcionados en la presente. Los anticuerpos descritos son utiles para el tratamiento de pacientes que sufren cáncer, especialmente cáncer de colon, pulmon o páncreas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09004905 | 2009-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076020A1 true AR076020A1 (es) | 2011-05-11 |
Family
ID=40673340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101066A AR076020A1 (es) | 2009-04-02 | 2010-03-31 | Anticuerpos contra la proteina tweak humana y usos de los mismos |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8093006B2 (es) |
| EP (2) | EP2597104A1 (es) |
| JP (1) | JP5596777B2 (es) |
| KR (1) | KR101344611B1 (es) |
| CN (1) | CN102369219A (es) |
| AR (1) | AR076020A1 (es) |
| AU (1) | AU2010233997A1 (es) |
| BR (1) | BRPI1014867A2 (es) |
| CA (1) | CA2756245A1 (es) |
| CL (1) | CL2011002452A1 (es) |
| CO (1) | CO6362025A2 (es) |
| CR (1) | CR20110462A (es) |
| EC (1) | ECSP11011362A (es) |
| IL (1) | IL214355A0 (es) |
| MA (1) | MA33097B1 (es) |
| MX (1) | MX2011010117A (es) |
| NZ (1) | NZ594347A (es) |
| PE (1) | PE20120577A1 (es) |
| RU (1) | RU2011143903A (es) |
| SG (2) | SG10201404107SA (es) |
| TW (1) | TWI423815B (es) |
| UA (1) | UA105520C2 (es) |
| WO (1) | WO2010115555A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8093006B2 (en) * | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
| US9526846B2 (en) | 2009-08-19 | 2016-12-27 | Safety Syringes, Inc. | Patient-contact activated needle stick safety device |
| US9068004B2 (en) | 2010-02-04 | 2015-06-30 | University Of Louisville Research Foundation, Inc. | TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration |
| BR112013007293A2 (pt) | 2010-10-05 | 2016-06-14 | Hoffmann La Roche | anticorpos contra a tweak de seres humanos e suas utilizações |
| EP2683740B1 (en) | 2011-03-10 | 2018-07-04 | Omeros Corporation | Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
| EP2834273B1 (en) | 2012-04-05 | 2018-08-22 | F.Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| JP2016000003A (ja) * | 2013-04-19 | 2016-01-07 | アステラス製薬株式会社 | 新規抗ヒトｔｗｅａｋ抗体 |
| CN103399151A (zh) * | 2013-06-24 | 2013-11-20 | 上海交通大学医学院附属瑞金医院 | Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用 |
| JP7415939B2 (ja) * | 2018-10-31 | 2024-01-17 | アステラス製薬株式会社 | 抗ヒトＦｎ１４抗体 |
| WO2025005938A1 (en) * | 2023-06-26 | 2025-01-02 | Memorial Sloan-Kettering Cancer Center | Antibodies and antigen binding fragments thereof binding to chimeric receptors and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US7129061B1 (en) | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
| SI0956351T1 (sl) | 1996-08-07 | 2006-02-28 | Biogen Idec Inc | Ligand, sosroden faktorju tumorske nekroze |
| CA2280231A1 (en) | 1997-02-12 | 1998-08-13 | Abbott Laboratories | Member of the tnf family useful for treatment and diagnosis of disease |
| ATE319745T1 (de) | 1997-05-21 | 2006-03-15 | Biovation Ltd | Verfahren zur herstellung von nicht-immunogenen proteinen |
| EP1967587A1 (en) | 1997-10-10 | 2008-09-10 | Genentech, Inc. | APO-3 Ligand |
| HUP0105044A3 (en) * | 1999-01-15 | 2004-07-28 | Biogen Inc Cambridge | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| AU2937300A (en) | 1999-03-04 | 2000-09-21 | Vision Sciences, Inc. | Image sensor's unit cell with individually controllable electronic shutter circuit |
| GB9922069D0 (en) | 1999-09-17 | 1999-11-17 | Technolog Ltd | Water distribution pressure control method and apparatus |
| WO2001030374A1 (en) | 1999-10-22 | 2001-05-03 | The University Of Pittsburgh | Stem cell engraftment-enhancing cellular proteins and their uses |
| AU8028400A (en) | 1999-10-22 | 2001-05-08 | Scimed Life Systems, Inc. | Guided injection device |
| JP5148795B2 (ja) | 1999-12-20 | 2013-02-20 | イミュネックス・コーポレーション | Ｔｗｅａｋ受容体 |
| NZ522741A (en) | 2000-05-08 | 2005-06-24 | Biogen Idec Inc | Method for promoting neovascularization using a TWEAK agonist and an angiogenic factor, such as fibroblast growth factor and VEGF |
| US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| MXPA04009683A (es) | 2002-04-09 | 2005-01-11 | Biogen Idec Inc | Metodos para el tratamiento de condiciones relacionadas a tweak. |
| EP1811838A4 (en) | 2004-11-08 | 2009-07-22 | Univ Maryland | TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH |
| US7939490B2 (en) | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| WO2006088890A2 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating stroke |
| DK2332408T3 (da) | 2005-02-17 | 2013-12-02 | Biogen Idec Inc | Behandling af neurologiske sygdomme |
| EP1853312B1 (en) | 2005-03-07 | 2014-12-10 | Genentech, Inc. | Methods and compositions for modulating tweak and fn14 activity |
| CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| WO2006130429A2 (en) | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| CN102441163A (zh) * | 2005-05-27 | 2012-05-09 | 比奥根艾迪克Ma公司 | 结合tweak的抗体 |
| US8093006B2 (en) * | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
-
2010
- 2010-03-29 US US12/748,487 patent/US8093006B2/en not_active Expired - Fee Related
- 2010-03-30 CN CN2010800143842A patent/CN102369219A/zh active Pending
- 2010-03-30 BR BRPI1014867A patent/BRPI1014867A2/pt not_active IP Right Cessation
- 2010-03-30 JP JP2012502506A patent/JP5596777B2/ja not_active Expired - Fee Related
- 2010-03-30 RU RU2011143903/10A patent/RU2011143903A/ru not_active Application Discontinuation
- 2010-03-30 MA MA34141A patent/MA33097B1/fr unknown
- 2010-03-30 SG SG10201404107SA patent/SG10201404107SA/en unknown
- 2010-03-30 MX MX2011010117A patent/MX2011010117A/es active IP Right Grant
- 2010-03-30 SG SG2011071487A patent/SG175005A1/en unknown
- 2010-03-30 EP EP13153217.8A patent/EP2597104A1/en not_active Withdrawn
- 2010-03-30 WO PCT/EP2010/002009 patent/WO2010115555A2/en not_active Ceased
- 2010-03-30 KR KR1020117023045A patent/KR101344611B1/ko not_active Expired - Fee Related
- 2010-03-30 NZ NZ594347A patent/NZ594347A/xx not_active IP Right Cessation
- 2010-03-30 AU AU2010233997A patent/AU2010233997A1/en not_active Abandoned
- 2010-03-30 PE PE2011001689A patent/PE20120577A1/es not_active Application Discontinuation
- 2010-03-30 CA CA2756245A patent/CA2756245A1/en not_active Abandoned
- 2010-03-30 UA UAA201112304A patent/UA105520C2/uk unknown
- 2010-03-30 EP EP10717039A patent/EP2414398A2/en not_active Withdrawn
- 2010-03-31 AR ARP100101066A patent/AR076020A1/es unknown
- 2010-03-31 TW TW099109987A patent/TWI423815B/zh not_active IP Right Cessation
-
2011
- 2011-07-28 IL IL214355A patent/IL214355A0/en unknown
- 2011-08-24 CO CO11108197A patent/CO6362025A2/es active IP Right Grant
- 2011-08-26 CR CR20110462A patent/CR20110462A/es unknown
- 2011-09-30 EC EC2011011362A patent/ECSP11011362A/es unknown
- 2011-09-30 CL CL2011002452A patent/CL2011002452A1/es unknown
- 2011-11-02 US US13/287,256 patent/US8852887B2/en not_active Expired - Fee Related
-
2012
- 2012-03-23 US US13/427,951 patent/US8883976B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010115555A2 (en) | 2010-10-14 |
| US20100255008A1 (en) | 2010-10-07 |
| KR101344611B1 (ko) | 2013-12-30 |
| MX2011010117A (es) | 2011-10-14 |
| BRPI1014867A2 (pt) | 2016-04-12 |
| RU2011143903A (ru) | 2013-05-10 |
| IL214355A0 (en) | 2011-09-27 |
| TW201039847A (en) | 2010-11-16 |
| AU2010233997A1 (en) | 2011-08-18 |
| US8883976B2 (en) | 2014-11-11 |
| JP2012521771A (ja) | 2012-09-20 |
| US20120083015A1 (en) | 2012-04-05 |
| CN102369219A (zh) | 2012-03-07 |
| EP2414398A2 (en) | 2012-02-08 |
| US8093006B2 (en) | 2012-01-10 |
| EP2597104A1 (en) | 2013-05-29 |
| SG175005A1 (en) | 2011-11-28 |
| MA33097B1 (fr) | 2012-03-01 |
| TWI423815B (zh) | 2014-01-21 |
| CA2756245A1 (en) | 2010-10-14 |
| US20120207750A1 (en) | 2012-08-16 |
| CO6362025A2 (es) | 2012-01-20 |
| ECSP11011362A (es) | 2011-10-31 |
| US8852887B2 (en) | 2014-10-07 |
| KR20110122868A (ko) | 2011-11-11 |
| SG10201404107SA (en) | 2014-10-30 |
| NZ594347A (en) | 2012-09-28 |
| JP5596777B2 (ja) | 2014-09-24 |
| PE20120577A1 (es) | 2012-05-23 |
| WO2010115555A3 (en) | 2011-01-06 |
| CL2011002452A1 (es) | 2012-03-23 |
| UA105520C2 (uk) | 2014-05-26 |
| CR20110462A (es) | 2011-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076020A1 (es) | Anticuerpos contra la proteina tweak humana y usos de los mismos | |
| EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
| EA201590986A1 (ru) | Антитела к ceacam5 и их применения | |
| AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
| AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
| UY31862A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
| AR074756A1 (es) | Anticuerpos contra la angiopoyetina-2 humana | |
| UY31861A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
| AR090047A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
| UY32603A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
| EA201492149A1 (ru) | St2-антигенсвязывающие белки | |
| NZ754051A (en) | Novel antibodies and uses thereof | |
| CO6680687A2 (es) | Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas | |
| CO6351751A2 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos | |
| CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
| MX338754B (es) | Anticuerpos humanos contra el factor tisular. | |
| CY1117922T1 (el) | Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων | |
| AR085955A1 (es) | Proteinas de union al antigeno | |
| AR073072A1 (es) | Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano | |
| CR20120154A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| AR063829A1 (es) | Moleculas de enlace de lingo y uso farmaceutico de las mismas | |
| AR080794A1 (es) | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 | |
| EA200870021A1 (ru) | Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител | |
| CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |